Multikinase inhibitors use in differentiated thyroid carcinoma

References

• SiegelRMaJZouZJemalACancer statistics, 2014CA Cancer J Clin201464192924399786
   PubMed Web of Science ®Google Scholar
• American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid CancerCooperDSDohertyGMHaugenBRRevised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancerThyroid200919111167121419860577
   PubMed Web of Science ®Google Scholar
• HundahlSAFlemingIDFremgenAMMenckHRA National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985–1995 [see comments]Cancer19988312263826489874472
   PubMed Web of Science ®Google Scholar
• DaviesLWelchHGIncreasing incidence of thyroid cancer in the United States, 1973–2002JAMA2006295182164216716684987
   PubMed Web of Science ®Google Scholar
• YousermDMHuangTLoevnerLALanglotzCPClinical and economic impact of incidental thyroid lesions found with CT and MRAm J Neuroradiol1997188142314289296181
   PubMed Web of Science ®Google Scholar
• CronanJJThyroid nodules: is it time to turn off the US machines?Radiology2008247360260418487528
   PubMed Web of Science ®Google Scholar
• Aschebrook-KilfoyBGroganRHWardMHKaplanEDevesaSSFollicular thyroid cancer incidence patterns in the United States, 1980–2009Thyroid20132381015102123360496
   PubMed Web of Science ®Google Scholar
• SoaresPCelestinoRMeloMFonsecaESobrinho-SimoesMPrognostic biomarkers in thyroid cancerVirchows Arch2014464333334624487783
   PubMed Web of Science ®Google Scholar
• RussellMAGilbertEFJaeschkeWFPrognostic features of thyroid cancer. A long-term followup of 68 casesCancer19753625535591157018
   PubMed Web of Science ®Google Scholar
• HayIDThompsonGBGrantCSPapillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patientsWorld J Surg200226887988512016468
   PubMed Web of Science ®Google Scholar
• GillilandFDHuntWCMorrisDMKeyCRPrognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973–1991Cancer19977935645739028369
   PubMed Web of Science ®Google Scholar
• DeLellisRAPathology and Genetics of Tumours of Endocrine OrgansLyonIARC Press2004
   Google Scholar
• KondoTEzzatSAsaSLPathogenetic mechanisms in thyroid follicular-cell neoplasiaNat Rev Cancer20066429230616557281
   PubMed Web of Science ®Google Scholar
• XingMBRAF mutation in thyroid cancerEndocr Relat Cancer200512224526215947100
   PubMed Web of Science ®Google Scholar
• KimTHParkYJLimJAThe association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysisCancer201211871764177321882184
   PubMed Web of Science ®Google Scholar
• XingMMolecular pathogenesis and mechanisms of thyroid cancerNat Rev Cancer201313318419923429735
   PubMed Web of Science ®Google Scholar
• SoaresPSobrinho-SimoesMCancer: small papillary thyroid cancers – is BRAF of prognostic value?Nat Rev Endocrinol20117191021160471
   PubMed Web of Science ®Google Scholar
• PatelKNGenetic mutations, molecular markers and future directions in researchOral Oncol201349771172123602255
   PubMed Web of Science ®Google Scholar
• XingMPrognostic utility of BRAF mutation in papillary thyroid cancerMol Cell Endocrinol20103211869319883729
   PubMed Web of Science ®Google Scholar
• XingMGenetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancerThyroid201020769770620578891
   PubMed Web of Science ®Google Scholar
• EsapaCTJohnsonSJKendall-TaylorPLennardTWHarrisPEPrevalence of Ras mutations in thyroid neoplasiaClin Endocrinol1999504529535
   PubMed Web of Science ®Google Scholar
• NikiforovYENikiforovaMNMolecular genetics and diagnosis of thyroid cancerNat Rev Endocrinol201171056958021878896
   PubMed Web of Science ®Google Scholar
• BongarzoneIFugazzolaLVigneriPAge-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinomaJ Clin Endocrinol Metab1996815200620098626874
   PubMed Web of Science ®Google Scholar
• FentonCLLukesYNicholsonDDinauerCAFrancisGLTuttleRMThe ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adultsJ Clin Endocrinol Metab20008531170117510720057
   PubMed Web of Science ®Google Scholar
• GuerraASapioMRMarottaVPrevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical applicationEndocr J2011581313821173509
   PubMed Web of Science ®Google Scholar
• NikiforovaMNBiddingerPWCaudillCMKrollTGNikiforovYEPAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analysesAm J Surg Pathol20022681016102312170088
   PubMed Web of Science ®Google Scholar
• MazzaferriELJhiangSMLong-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancerAm J Med19949754184287977430
   PubMed Web of Science ®Google Scholar
• NixonIJWhitcherMMPalmerFLThe impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid glandThyroid201222988488922827579
   PubMed Web of Science ®Google Scholar
• MihailovicJStefanovicLMalesevicMDifferentiated thyroid carcinoma with distant metastases: probability of survival and its predicting factorsCancer Biother Radiopharm200722225025517600472
   PubMed Web of Science ®Google Scholar
• DinneenSFValimakiMJBergstralhEJGoellnerJRGormanCAHayIDDistant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decadesJ Clin Endocrinol Metab1995807204120457608252
   PubMed Web of Science ®Google Scholar
• CaplanRHStruttPJWickusGGSubclinical hormone secretion by incidentally discovered adrenal massesArch Surg199412932912968129606
   PubMedGoogle Scholar
• SchlumbergerMBroseMEliseiRDefinition and management of radioactive iodine-refractory differentiated thyroid cancerLancet Diabetes Endocrinol20142535635824795243
   PubMed Web of Science ®Google Scholar
• SacksWBraunsteinGDEvolving approaches in managing radioactive iodine-refractory differentiated thyroid cancerEndocr Pract201420326327524126232
   PubMed Web of Science ®Google Scholar
• BusaidyNLCabanillasMEDifferentiated thyroid cancer: management of patients with radioiodine nonresponsive diseaseJ Thyroid Res2012201261898522530159
   PubMedGoogle Scholar
• HaugenBRManagement of the patient with progressive radioiodine non-responsive diseaseSemin Surg Oncol199916134419890738
   PubMedGoogle Scholar
• HaugenBRShermanSIEvolving approaches to patients with advanced differentiated thyroid cancerEndocr Rev201334343945523575762
   PubMed Web of Science ®Google Scholar
• MorabitoADe MaioEDi MaioMNormannoNPerroneFTyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directionsOncologist200611775376416880234
   PubMed Web of Science ®Google Scholar
• KorpantyGSmythEAnti-VEGF strategies – from antibodies to tyrosine kinase inhibitors: background and clinical development in human cancerCurr Pharm Des201218192680270122390756
   PubMed Web of Science ®Google Scholar
• ThomasLLaiSYDongWSorafenib in metastatic thyroid cancer: a systematic reviewOncologist201419325125824563075
   PubMed Web of Science ®Google Scholar
• DaduRWaguespackSGShermanSIEfficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancerOncologist201419547748224733667
   PubMed Web of Science ®Google Scholar
• HoftijzerHHeemstraKAMorreauHBeneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinomaEur J Endocrinol2009161692393119773371
   PubMed Web of Science ®Google Scholar
• WilhelmSChienDSBAY 43-9006: preclinical dataCurr Pharm Des20028252255225712369853
   PubMed Web of Science ®Google Scholar
• KloosRTRingelMDKnoppMVPhase II trial of sorafenib in metastatic thyroid cancerJ Clin Oncol200927101675168419255327
   PubMed Web of Science ®Google Scholar
• Gupta-AbramsonVTroxelABNelloreAPhase II trial of sorafenib in advanced thyroid cancerJ Clin Oncol200826294714471918541894
   PubMed Web of Science ®Google Scholar
• SchneiderTCAbdulrahmanRMCorssmitEPMorreauHSmitJWKapiteijnELong-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trialEur J Endocrinol2012167564365022918300
   PubMed Web of Science ®Google Scholar
• AhmedMBarbachanoYRiddellAAnalysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based populationEur J Endocrinol2011165231532221566072
   PubMed Web of Science ®Google Scholar
• BroseMSNuttingCJarzabBSorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the phase 3 DECISION trialOncol Res Treat201437130131
   Web of Science ®Google Scholar
• BroseMSNuttingCMJarzabBDECISION InvestigatorsSorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialLancet2014384994031932824768112
   PubMed Web of Science ®Google Scholar
• CarhillAACabanillasMEJimenezCThe noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoringJ Clin Endocrinol Metab2013981314223185034
   PubMed Web of Science ®Google Scholar
• ChenLShenYLuoQYuYLuHZhuRResponse to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinomaThyroid201121211912421186953
   PubMed Web of Science ®Google Scholar
• ShenYRuanMLuoQBrain metastasis from follicular thyroid carcinoma: treatment with sorafenibThyroid201222885686022793259
   PubMed Web of Science ®Google Scholar
• HoukBEBelloCLKangDAmanteaMA population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patientsClin Cancer Res20091572497250619258444
   PubMed Web of Science ®Google Scholar
• CohenEENeedlesBMCullenKJPhase 2 study of sunitinib in refractory thyroid cancerJ Clin Oncol200826156025
   Web of Science ®Google Scholar
• CarrLLMankoffDAGoulartBHPhase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlationClin Cancer Res201016215260526820847059
   PubMed Web of Science ®Google Scholar
• PolverinoACoxonAStarnesCAMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors, potently inhibits angiogenesis and induces regression in tumor xenograftsCancer Res200666178715872116951187
   PubMed Web of Science ®Google Scholar
• RosenLSKurzrockRMulayMSafety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumorsJ Clin Oncol200725172369237617557949
   PubMed Web of Science ®Google Scholar
• ShermanSIWirthLJDrozJPMotesanib diphosphate in progressive differentiated thyroid cancerN Engl J Med20083591314218596272
   PubMed Web of Science ®Google Scholar
• InaiTMancusoMHashizumeHInhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghostsAm J Pathol20041651355215215160
   PubMed Web of Science ®Google Scholar
• RugoHSHerbstRSLiuGPhase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical resultsJ Clin Oncol200523245474548316027439
   PubMed Web of Science ®Google Scholar
• CohenEEWRosenLSVokesEEAxitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II studyJ Clin Oncol200826294708471318541897
   PubMed Web of Science ®Google Scholar
• LocatiLDLicitraLAgateLTreatment of advanced thyroid cancer with axitinib: phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessmentsCancer2014120172694270324844950
   PubMed Web of Science ®Google Scholar
• BibleKCSumanVJMolinaJREfficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium studyLancet Oncol2010111096297220851682
   PubMed Web of Science ®Google Scholar
• MatsuiJFunahashiYUenakaTWatanabeTTsuruokaAAsadaMMulti-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinaseClin Cancer Res200814175459546518765537
   PubMed Web of Science ®Google Scholar
• BossDSGlenHBeijnenJHA phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumoursBr J Cancer2012106101598160422516948
   PubMed Web of Science ®Google Scholar
• ShermanSIJarzabBCabanillasMEA phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC)J Clin Oncol20112915 abstr5503
   Web of Science ®Google Scholar
• SchlumbergerMTaharaMWirthLJA phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131 I-refractory differentiated thyroid cancer (SELECT)J Clin Oncol2014325s abstrLBA6008
   Google Scholar
• RahmanMASalajeghehASmithRALamAKBRAF inhibitors: from the laboratory to clinical trialsCrit Rev Oncol Hematol201490322023224388103
   PubMed Web of Science ®Google Scholar
• RoskoskiRRAF protein-serine/threonine kinases: structure and regulationBiochem Biophys Res Commun2010399331331720674547
   PubMed Web of Science ®Google Scholar
• BollagGHirthPTsaiJClinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature2010467731559659920823850
   PubMed Web of Science ®Google Scholar
• YangHHigginsBKolinskyKRG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma modelsCancer Res201070135518552720551065
   PubMed Web of Science ®Google Scholar
• KimKBCabanillasMELazarAJClinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutationThyroid201323101277128323489023
   PubMed Web of Science ®Google Scholar
• FalchookGSLongGVKurzrockRDabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialLancet201237998291893190122608338
   PubMed Web of Science ®Google Scholar
• TrujilloJIMEK inhibitors: a patent review 2008–2010Expert Opin Ther Pat20112171045106921548849
   PubMed Web of Science ®Google Scholar
• HoALGrewalRKLeboeufRSelumetinib-enhanced radioiodine uptake in advanced thyroid cancerN Engl J Med2013368762363223406027
   PubMed Web of Science ®Google Scholar
• FlahertyKTRobertCHerseyPMETRIC Study GroupImproved survival with MEK inhibition in BRAF-mutated melanomaN Engl J Med2012367210711422663011
   PubMed Web of Science ®Google Scholar
• de SouzaECLFerreiraACFde CarvalhoDPThe mTOR protein as a target in thyroid cancerExpert Opin Ther Targets20111591099111221702716
   PubMed Web of Science ®Google Scholar
• LimSMChangHYoonMJA multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypesAnn Oncol201324123089309424050953
   PubMed Web of Science ®Google Scholar
• EbosJMLeeCRCruz-MunozWBjarnasonGAChristensenJGKerbelRSAccelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesisCancer Cell200915323223919249681
   PubMed Web of Science ®Google Scholar
• FuerederTJaeger-LanskyAHoeflmayerDmTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivoCancer Lett2010296224925620471160
   PubMed Web of Science ®Google Scholar
• LaneHAWoodJMMcSheehyPMmTOR Inhibitor RAD001 (Everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitorClin Cancer Res20091551612162219223496
   PubMed Web of Science ®Google Scholar
• ShermanEJHoALFuryMGPhase II study of everolimus and sorafenib for the treatment of metastatic thyroid cancerJ Clin Oncol20133115 abstr6024
   Google Scholar
• SolitDBRosenNResistance to BRAF inhibition in melanomasN Engl J Med2011364877277421345109
   PubMed Web of Science ®Google Scholar
• FlahertyKTInfanteJRDaudACombined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsN Engl J Med2012367181694170323020132
   PubMed Web of Science ®Google Scholar
• EcksteinNRöperLHaasBClinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspectiveJ Exp Clin Cancer Res2014331524502453
   PubMed Web of Science ®Google Scholar
• JosephsDHFisherDSSpicerJFlanaganRJClinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoringTher Drug Monit201335556258724052062
   PubMed Web of Science ®Google Scholar
• CabanillasMEHuMIDurandJBBusaidyNLChallenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancerJ Thyroid Res2011201198578022007339
   PubMedGoogle Scholar
• KandulaPAgarwalRProteinuria and hypertension with tyrosine kinase inhibitorsKidney Int201180121271127721900879
   PubMed Web of Science ®Google Scholar
• HayesDNLucasASTanvetyanonTPhase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elementsClin Cancer Res20121872056206522241789
   PubMed Web of Science ®Google Scholar